{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:26:08Z","timestamp":1793996768524,"version":"4.8.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1345,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulness of the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular risk in CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events (AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A retrospective single-centre observational study was carried out on 58 patients (32 men and 26 women; mean age \u00b1 SD: 59 \u00b1 15 years) with CML treated with TKIs for a median period of 43 \u00b1 31 months. Cardiological evaluation was performed and cardiovascular risk was estimated with SCORE risk charts and with the new risk assessment tool proposed by HFA\/ICOS. AEs were recorded. According to SCORE charts and the new HFA\/ICOS risk stratification tool, respectively, 46% (Group A1) and 60% (Group A2) of patients were at high\u2013very high risk, and 54% (Group B1) and 40% (Group B2) at low\u2013moderate risk. AEs were significantly more frequent in Group A1 than Group B1 (P value &amp;lt; 0.01) when considered overall; they were significantly more frequent in Group A2 than Group B2 either overall or considered individually. HFA\/ICOS risk stratification tool was significantly more sensitive than SCORE (P &amp;lt; 0.01) in identifying patients at higher risk of cardiovascular toxicity. In addition, we did not find AEs in patients pretreated with aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The new HFA\/ICOS risk stratification model allows a more tailored cardiovascular risk stratification in patients with CML and it is more sensitive than SCORE charts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13897","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T03:46:42Z","timestamp":1648698402000},"page":"1914-1919","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The New HFA\/ICOS Risk Assessment Tool to Identify Patients with Chronic Myeloid Leukaemia at High Risk of Cardiotoxicity"],"prefix":"10.1093","volume":"9","author":[{"given":"Daniela","family":"Di Lisi","sequence":"first","affiliation":[{"name":"Cardiology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Madaudo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Alagna","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]},{"name":"Haematology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Rossetto","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]},{"name":"Haematology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University Hospital Paolo Giaccone , Palermo ,","place":["Italy"]},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"2026012114233241900_ehf213897-bib-0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026012114233241900_ehf213897-bib-0002","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026012114233241900_ehf213897-bib-0003","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2026012114233241900_ehf213897-bib-0004","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012114233241900_ehf213897-bib-0005","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardiooncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"},{"key":"2026012114233241900_ehf213897-bib-0006","first-page":"852","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can J Cardiol"},{"key":"2026012114233241900_ehf213897-bib-0007","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10741-020-09926-y","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026012114233241900_ehf213897-bib-0008","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114233241900_ehf213897-bib-0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann Hematol"},{"key":"2026012114233241900_ehf213897-bib-0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"2026012114233241900_ehf213897-bib-0011","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","article-title":"Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib","volume":"100","author":"Caocci","year":"2021","journal-title":"Ann Hematol"},{"key":"2026012114233241900_ehf213897-bib-0012","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114233241900_ehf213897-bib-0013","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"2026012114233241900_ehf213897-bib-0014","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114233241900_ehf213897-bib-0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114233241900_ehf213897-bib-0016","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114233241900_ehf213897-bib-0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2010.01.019","article-title":"Preclinical carotid atherosclerosis enhances the global cardiovascular risk and increases the rate of cerebro-and cardiovascular events in a five-year follow-up","volume":"211","author":"Novo","year":"2010","journal-title":"Atherosclerosis"},{"key":"2026012114233241900_ehf213897-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114233241900_ehf213897-bib-0019","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114233241900_ehf213897-bib-0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","article-title":"Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: the HFA\/ICOS risk tool in real-world practice","volume":"349","author":"Tini","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026012114233241900_ehf213897-bib-0021","doi-asserted-by":"crossref","first-page":"E159","DOI":"10.1002\/ajh.25102","article-title":"Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis","volume":"93","author":"Caocci","year":"2018","journal-title":"Am J Hematol"},{"key":"2026012114233241900_ehf213897-bib-0022","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13897","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/3\/1914\/65668846\/eschf_9_3_1914.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/3\/1914\/65668846\/eschf_9_3_1914.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:29:22Z","timestamp":1769023762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/3\/1914\/8362431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13897","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2021-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}